Auvi-Q
- Product NDC
- 85766-277
- 11-digit product format
- 857660277
- Labeler code
- 85766
- Product ID
- 85766-277_5bbbd802-1766-6081-e063-6294a90af4a5
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- epinephrine
- Dosage form
- INJECTION, SOLUTION
- Route
- INTRAMUSCULAR
- Labeler
- Sportpharm LLC
- Application
- NDA201739
- Marketing category
- NDA
- Marketing start
- 2012-11-15
- Substance
- EPINEPHRINE
- Active strength
- .3 mg/.3mL
- Pharmacologic classes
- Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Catecholamine [EPC], Catecholamines [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N201739-001 | AUVI-Q | EPINEPHRINE | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 |
| N201739-002 | AUVI-Q | EPINEPHRINE | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 |
| N201739-003 | AUVI-Q | EPINEPHRINE | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N201739-001 | BX |
| N201739-002 | BX |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N201739-001 | 11590286 | 2026-12-12 | Drug product | 2023-03-29 | |
| N201739-001 | 8206360 | 2027-02-27 | Drug product | 2013-03-21 | |
| N201739-001 | 7947017 | 2028-03-12 | Drug product | 2013-02-22 | |
| N201739-001 | 8231573 | 2028-11-25 | Drug product | 2012-08-21 | |
| N201739-001 | 8226610 | 2029-04-10 | Drug product | 2012-08-21 | |
| N201739-001 | 8021344 | 2029-11-02 | Drug product | 2013-07-26 | |
| N201739-002 | 11590286 | 2026-12-12 | Drug product | 2023-03-29 | |
| N201739-002 | 8206360 | 2027-02-27 | Drug product | ||
| N201739-002 | 7947017 | 2028-03-12 | Drug product | ||
| N201739-002 | 8231573 | 2028-11-25 | Drug product | ||
| N201739-002 | 8226610 | 2029-04-10 | Drug product | ||
| N201739-002 | 8021344 | 2029-11-02 | Drug product | 2013-07-26 | |
| N201739-002 | 10688244 | 2037-12-21 | U-2980 | Drug product | 2020-11-04 |
| N201739-002 | 10842938 | 2037-12-21 | U-2980 | Drug product | 2020-12-10 |
| N201739-002 | 11771830 | 2037-12-21 | U-2980 | Drug product | 2023-12-20 |
| N201739-003 | 11590286 | 2026-12-12 | Drug product | 2023-03-29 | |
| N201739-003 | 8206360 | 2027-02-27 | Drug product | 2017-12-15 | |
| N201739-003 | 7947017 | 2028-03-12 | Drug product | 2017-12-15 | |
| N201739-003 | 8231573 | 2028-11-25 | Drug product | 2017-12-15 | |
| N201739-003 | 8226610 | 2029-04-10 | Drug product | 2017-12-15 | |
| N201739-003 | 8021344 | 2029-11-02 | Drug product | 2017-12-15 | |
| N201739-003 | 10688244 | 2037-12-21 | U-2980 | Drug product | 2020-11-04 |
| N201739-003 | 10842938 | 2037-12-21 | U-2980 | Drug product | 2020-12-10 |
| N201739-003 | 11771830 | 2037-12-21 | U-2980 | Drug product | 2023-12-20 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N201739-002 | AUVI-Q | EQ 0.15MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD, RS | 2012-08-10 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N201739-003 | AUVI-Q | EQ 0.1MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | RLD | 2017-11-17 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N201739-001 | AUVI-Q | EQ 0.3MG/DELIVERY | SOLUTION / INTRAMUSCULAR, SUBCUTANEOUS | BX | RLD | 2012-08-10 | 301d65b070ca… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N201739-001 | BX | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | BX | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N201739-001 | BX | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | BX | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N201739-001 | BX | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N201739-002 | BX | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N201739-001 | BX | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N201739-002 | BX | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N201739-001 | BX | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N201739-002 | BX | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N201739-001 | BX | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N201739-002 | BX | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N201739-001 | BX | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N201739-002 | BX | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N201739-001 | BX | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N201739-002 | BX | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N201739-001 | BX | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N201739-002 | BX | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N201739-001 | BX | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N201739-002 | BX | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N201739-001 | BX | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N201739-002 | BX | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N201739-001 | BX | 1 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | N201739-002 | BX | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N201739-001 | BX | 1 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N201739-002 | BX | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N201739-001 | BX | 1 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N201739-002 | BX | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N201739-001 | BX | 1 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N201739-002 | BX | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N201739-001 | BX | 1 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | N201739-002 | BX | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N201739-001 | BX | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N201739-002 | BX | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N201739-001 | BX | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | N201739-002 | BX | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N201739-001 | BX | 1 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | N201739-002 | BX | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N201739-001 | BX | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N201739-002 | BX | 1 | 74a2ff9319b5… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N201739-001 | 11590286 | 2026-12-12 | Drug product | 2023-03-29 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-001 | 8206360 | 2027-02-27 | Drug product | 2013-03-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-001 | 7947017 | 2028-03-12 | Drug product | 2013-02-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-001 | 8231573 | 2028-11-25 | Drug product | 2012-08-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-001 | 8226610 | 2029-04-10 | Drug product | 2012-08-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-001 | 8021344 | 2029-11-02 | Drug product | 2013-07-26 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | 11590286 | 2026-12-12 | Drug product | 2023-03-29 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | 8206360 | 2027-02-27 | Drug product | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | 7947017 | 2028-03-12 | Drug product | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | 8231573 | 2028-11-25 | Drug product | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | 8226610 | 2029-04-10 | Drug product | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | 8021344 | 2029-11-02 | Drug product | 2013-07-26 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | 10688244 | 2037-12-21 | U-2980 | Drug product | 2020-11-04 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | 10842938 | 2037-12-21 | U-2980 | Drug product | 2020-12-10 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N201739-002 | 11771830 | 2037-12-21 | U-2980 | Drug product | 2023-12-20 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | 11590286 | 2026-12-12 | Drug product | 2023-03-29 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | 8206360 | 2027-02-27 | Drug product | 2017-12-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | 7947017 | 2028-03-12 | Drug product | 2017-12-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | 8231573 | 2028-11-25 | Drug product | 2017-12-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | 8226610 | 2029-04-10 | Drug product | 2017-12-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | 8021344 | 2029-11-02 | Drug product | 2017-12-15 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | 10688244 | 2037-12-21 | U-2980 | Drug product | 2020-11-04 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | 10842938 | 2037-12-21 | U-2980 | Drug product | 2020-12-10 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N201739-003 | 11771830 | 2037-12-21 | U-2980 | Drug product | 2023-12-20 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N201739-001 | 11590286 | 2026-12-12 | Drug product | 2023-03-29 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N201739-001 | 8206360 | 2027-02-27 | Drug product | 2013-03-21 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N201739-001 | 7947017 | 2028-03-12 | Drug product | 2013-02-22 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N201739-001 | 8231573 | 2028-11-25 | Drug product | 2012-08-21 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N201739-001 | 8226610 | 2029-04-10 | Drug product | 2012-08-21 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N201739-001 | 8021344 | 2029-11-02 | Drug product | 2013-07-26 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | 11590286 | 2026-12-12 | Drug product | 2023-03-29 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | 8206360 | 2027-02-27 | Drug product | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | 7947017 | 2028-03-12 | Drug product | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | 8231573 | 2028-11-25 | Drug product | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | 8226610 | 2029-04-10 | Drug product | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | 8021344 | 2029-11-02 | Drug product | 2013-07-26 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | 10688244 | 2037-12-21 | U-2980 | Drug product | 2020-11-04 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | 10842938 | 2037-12-21 | U-2980 | Drug product | 2020-12-10 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N201739-002 | 11771830 | 2037-12-21 | U-2980 | Drug product | 2023-12-20 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N201739-003 | 11590286 | 2026-12-12 | Drug product | 2023-03-29 | caaa826d4ba7… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Auvi-Q
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| EPINEPHRINE | .3 mg/.3mL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Auvi-Q | EPINEPHRINE | kaleo, Inc | 6180fb40-7fca-4602-b3da-ce62b8cd2470 | 2025-10-02 | Warnings, Adverse reactions | 201739 NDA201739 |
| AUVI-Q | AUVI-Q | HF Acquisition Co LLC, DBA HealthFirst | 23e772f8-26d0-b516-e063-6394a90ada58 | 2025-05-07 | Warnings, Adverse reactions | 201739 NDA201739 |
| Auvi-Q | EPINEPHRINE | Medical Purchasing Solutions, LLC | 296a9023-b5c6-6102-e063-6294a90af87e | 2024-12-16 | Warnings, Adverse reactions | 201739 NDA201739 |
| Auvi-Q | EPINEPHRINE | Medical Purchasing Solutions, LLC | 29299266-69c5-b1a7-e063-6394a90a25f8 | 2024-12-13 | Warnings, Adverse reactions | 201739 NDA201739 |
| AUVI-Q | AUVI-Q | HF Acquisition Co LLC, DBA HealthFirst | 23fd4c93-0a42-922e-e063-6394a90a1887 | 2024-10-08 | Warnings, Adverse reactions | 201739 NDA201739 |
| AUVI-Q | AUVI-Q | HF Acquisition Co LLC, DBA HealthFirst | 23fdb616-0c60-44fe-e063-6394a90ad8f1 | 2024-10-08 | Warnings, Adverse reactions | 201739 NDA201739 |
| EPINEPHRINE | EPINEPHRINE | HF Acquisition Co LLC, DBA HealthFirst | 98aaa648-fc25-754d-e053-2995a90a7051 | 2024-03-08 | Warnings, Adverse reactions | 201739 NDA201739 |
| EPINEPHRINE | EPINEPHRINE | HF Acquisition Co LLC, DBA HealthFirst | 7664bb0d-dc1a-ca8b-e053-2991aa0ad627 | 2024-02-19 | Warnings, Adverse reactions | 201739 NDA201739 |
| Auvi-Q | EPINEPHRINE | Medical Purchasing Solutions, LLC | 8f110633-bf37-458d-e053-2a95a90a8fa9 | 2023-04-26 | Warnings, Adverse reactions | 201739 NDA201739 |
| Auvi-Q | EPINEPHRINE | Medical Purchasing Solutions, LLC | 8f00231e-be88-49fe-e053-2a95a90ab6dd | 2023-04-26 | Warnings, Adverse reactions | 201739 NDA201739 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 85766-277-02 | 85766027702 | 2 DOSE PACK in 1 CARTON (85766-277-02) / .3 mL in 1 DOSE PACK | 2 dose pack | 2026-09-18 | No | No | Current |